Docetaxel and Gemcitabine in Treating Patients With Progressive Regional or Metastatic Bladder Cancer [clinicaltrials:NCT00004223]
Docetaxel and Gemcitabine in Treating Patients With Progressive Regional or Metastatic Bladder Cancer [clinicaltrials:NCT00004223]
Bio2RDF identifier
NCT00004223
Bio2RDF namespace
clinicaltrials
Bio2RDF uri
http://bio2rdf.org/clinicaltrials:NCT00004223
identifiers.org URI
authority [clinicaltrials_vocabulary:authority]
brief summary [clinicaltrials_vocabulary:brief-summary]
RATIONALE: Drugs used i ...... or metastatic bladder cancer.
brief title [clinicaltrials_vocabulary:brief-title]
Docetaxel and Gemcitabine in T ...... l or Metastatic Bladder Cancer
collaborator [clinicaltrials_vocabulary:collaborator]
condition [clinicaltrials_vocabulary:condition]
condition browse [clinicaltrials_vocabulary:condition-browse]
condition mesh [clinicaltrials_vocabulary:condition-mesh]
country [clinicaltrials_vocabulary:country]
detailed description [clinicaltrials_vocabulary:detailed-description]
OBJECTIVES: I. Determin ...... tudy over 18-21
months.
download date [clinicaltrials_vocabulary:download-date]
ClinicalTrials.gov processed this data on August 10, 2015
eligibility [clinicaltrials_vocabulary:eligibility]
firstreceived date [clinicaltrials_vocabulary:firstreceived-date]
2000-01-28T00:00:00Z
has expanded access [clinicaltrials_vocabulary:has-expanded-access]
intervention [clinicaltrials_vocabulary:intervention]
intervention browse [clinicaltrials_vocabulary:intervention-browse]
is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]
is section 801 [clinicaltrials_vocabulary:is-section-801]
keyword [clinicaltrials_vocabulary:keyword]
metastatic transitional cell cancer of the renal pelvis and ureter
posterior urethral cancer
recurrent bladder cancer
regional transitional cell cancer of the renal pelvis and ureter
stage III bladder cancer
stage IV bladder cancer
transitional cell carcinoma of the bladder
lastchanged date [clinicaltrials_vocabulary:lastchanged-date]
2010-01-26T00:00:00Z
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
link [clinicaltrials_vocabulary:link]
location [clinicaltrials_vocabulary:location]
nct id [clinicaltrials_vocabulary:nct-id]
NCT00004223
official title [clinicaltrials_vocabulary:official-title]
Phase II Trial of Gemcitabine and Docetaxel in Advanced Carcinoma of the Urothelium
org study id [clinicaltrials_vocabulary:org-study-id]
CDR0000067464
overall official [clinicaltrials_vocabulary:overall-official]
overall status [clinicaltrials_vocabulary:overall-status]
oversight [clinicaltrials_vocabulary:oversight]
phase [clinicaltrials_vocabulary:phase]
primary completion date [clinicaltrials_vocabulary:primary-completion-date]
2002-10-01T00:00:00Z
responsible party [clinicaltrials_vocabulary:responsible-party]
secondary id [clinicaltrials_vocabulary:secondary-id]
source [clinicaltrials_vocabulary:source]
start date [clinicaltrials_vocabulary:start-date]
1999-12-01T00:00:00Z
study design [clinicaltrials_vocabulary:study-design]
study type [clinicaltrials_vocabulary:study-type]
url [clinicaltrials_vocabulary:url]
verification date [clinicaltrials_vocabulary:verification-date]
2010-01-01T00:00:00Z
identifier
clinicaltrials:NCT00004223
title
Docetaxel and Gemcitabine in T ...... l or Metastatic Bladder Cancer
@en
type
label
Docetaxel and Gemcitabine in T ...... r [clinicaltrials:NCT00004223]
@en